---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-169021"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:37:43.165070+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics stockholders approve equity plan expansion and re-elect directors at 2023 annual meeting

## Summary
- Stockholders approved Amended and Restated 2023 Equity Incentive Plan, increasing authorized shares by 1,150,000.
- Re-elected Thomas Dubensky and Christine Pellizzari as Class II directors to serve until 2026.
- Advisory vote on executive compensation approved with 7,355,907 votes for, 55,375 against.
- Ratified Ernst & Young as independent registered public accounting firm for fiscal 2023.

## SEC filing metadata
- accession: 0001193125-23-169021
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/d512429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-169021
- JSON: https://secwatch.observer/filing/0001193125-23-169021.json
- Plain text: https://secwatch.observer/filing/0001193125-23-169021.txt

## Key facts
- Shareholder Votes
  Tempest Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The Company’s stockholders elected the persons listed below as a Class II directors, to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm
- Shareholder Votes
  Tempest Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm
- Shareholder Votes
  Tempest Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm
- Shareholder Votes
  Tempest Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2023 Equity Incentive Plan at the 2023-06-15 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The Company’s stockholders ratified the 2023 EIP, which amends, restates and will be a successor to, and replacement of, the 2019 EIP.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.